

Neue Biologika zur Therapie chronisch-entzündlicher und autoimmuner rheumatischer Erkrankungen

Ingo H. Tarner, Johannes Strunk und Ulf Müller-Ladner, Bad Nauheim

Literatur

- Furst DE, Breedveld FC, Kalden JR, Smolen JS, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor α (TNF α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. *Ann Rheum Dis* 2005;64(Suppl III):iv2-iv14.
- Moreland L, Bate G, Kirkpatrick P. Abatacept. *Nature Rev Drug Discovery* 2006;5:185-6.
- Kavanaugh A. Health economics: implications for novel antirheumatic therapies. *Ann Rheum Dis* 2005;64(Suppl III):iv65-9.
- Lange U. Kosteneffektivität von Langzeittherapien unter besonderer Berücksichtigung der TNF- α -Hemmer. In: Müller-Ladner U (Hrsg.). *Evidenzbasierte Therapie in der Rheumatologie*. Bremen: UNI-MED Verlag, 2005: 96-104.
- McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. *Rheumatology* 2004;41:116-7.
- Criscione LG, St. Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. *Curr Opin Rheumatol* 2002;14: 204-11.
- Burmester GR, Monteagudo Saez I, Malaise MG, Canas da Silva J, et al. Adalimumab (Humira) is effective in patients who have previously been treated with TNF-antagonists (etanercept and/or infliximab) in widespread clinical practice: 12-week outcomes in the REACT trial. *Ann Rheum Dis* 2005;64(Suppl III):423.
- Nikas SN, Voulgari PV, Papadopoulos CG, Venetsanopoulou A, et al. The efficacy and safety of switching from infliximab to adalimumab. A prospective controlled study. *Ann Rheum Dis* 2005;64(Suppl III):422.
- Yang K, Basu A, Wang M, Chintala R, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. *Protein Engineering* 2003;16:761-70.
- Edwards CK 3rd, Martin SW, Seely J, Kinstler O, et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. *Adv Drug Deliv Rev* 2003;55:1315-36.
- Choy EHS, Hazleman B, Smith M, Moss K, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. *Rheumatology* 2002;41:1133-7.
- Rau R, Sander O, van Riel P, van de Putte L, et al., and the Rheumatology Study Group 791. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (Lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. *J Rheumatol* 2003;30:680-90.
- Hasler F, van de Putte L, Dumont E, et al. Safety and efficacy of TNF neutralization by lenercept in patients with rheumatoid arthritis exposed to a single dose. *Arthritis Rheum* 1996;39(Suppl):S243.
- Hasler F, van de Putte L, Baudin M, et al. Chronic TNF neutralization (up to 1 year) by lenercept (TNFR 55 IgG1, Ro 45-2081) in patients with rheumatoid arthritis exposed to a single dose. *Arthritis Rheum* 1996;39(Suppl):S243.
- Edwards CK 3rd. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. *Ann Rheum Dis* 1999;58(Suppl I):i73-81.
- Furst DE, Fleischmann R, Kopp E, Schiff M, et al. for the 990136 Study Group. A phase II dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. *J Rheumatol* 2005;32:2303-10.
- Klareskog L, van der Heijde D, de Jager JP, Gough A, et al. for the TEMPO (Trial of etanercept and methotrexate with radiographic patient outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;343:675-81.
- Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, et al. and the CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. *Gastroenterology* 2005;129:807-18.
- Webpage der U.S. National Institutes of Health: www.clinicaltrials.gov.
- Pollard L, Choy E. Rheumatoid arthritis: non-tumor necrosis factor targets. *Curr Opin Rheumatol* 2005;17:242-6.
- Woo P, Wilkinson N, Prieur AM, Southwood T, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. *Arthritis Res Ther* 2005;7:R1281-8.
- Yokota S, Miyamae T, Imagawa T, Iwata N, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum* 2005;52:818-25.
- Ito H, Takazoe M, Fukuda Y, Hibi T, et al. A pilot randomized trial of human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. *Gastroenterology* 2004;126:989-96.
- Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. *Blood* 2005;106:2627-32.
- Kunitomi A, Konaka Y, Yagita M, Nishimoto N, et al. Humanized anti-interleukin-6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune haemolytic anemia. *Int J Hematol* 2004;80:246-9.
- Choy EH, Isenberg DA, Garrood T, Farrow S, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. *Arthritis Rheum* 2002;46: 3143-50.
- Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;50:1761-9.
- Nishimoto N, Nakahara H, Terao K, Kakehi T, et al. Repeated treatments with anti-IL-6 receptor antibody (MRA) lead to an extended clinical response in rheumatoid arthritis even after cessation of MRA. *Arthritis Rheum* 2004;50(Suppl):S177.
- Creed TJ, Norman MR, Probert CSJ, Harvey RF, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. *Aliment Pharmacol Ther* 2003;18: 65-75.
- Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, et al. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-ranging trial. *Gut* 2006;Epub ahead of print.
- Bielekova B, Richert N, Howard T, Blevins G, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β . *Proc Natl Acad Sci USA* 2004;101:8705-8.
- Bielekova B, Calfano M, Reichert-Scriver S, Packer A, et al. Regulatory CD56 bright natural killer cells mediate immunomodulatory effects of IL-2R α -targeted therapy (daclizumab) in multiple sclerosis. *Proc Natl Acad Sci USA* 2006;103:5941-6.

Dr. Ingo H. Tarner, Dr. Johannes Strunk, Prof. Dr. Ulf Müller-Ladner, Lehrstuhl für Innere Medizin mit dem Schwerpunkt Rheumatologie der Justus-Liebig-Universität Gießen, Abteilung für Rheumatologie und klinische Immunologie, Kerckhoff-Klinik Bad Nauheim, Benekestr. 2-8, 61231 Bad Nauheim, E-Mail: i.tarner@kerckhoff-klinik.de

33. Scherer HU, Burmester GR, Riemekasten G. Targeting T-cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. *Ann Rheum Dis* 2005;64(Suppl III):303.
34. McInnes I, Martin R, Zimmerman-Gorska I, Nayjager S, et al. Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;50(Suppl): S241.
35. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. *Nature* 2005;435:612–9.
36. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. *Nat Rev Immunol* 2003;3:123–32.
37. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. *N Engl J Med* 2002;346:1692–8.
38. Bisikirska B, Colgan J, Luban J, Bluestone JA, et al. TCR stimulation with modified anti-CD3 mAb expands CD8⁺ T-cell population and induces CD8⁺CD25⁺ Tregs. *J Clin Invest* 2005;115:2904–13.
39. Herold KC, Gitelman SE, Masharani U, Hagopian W, et al. A single course of anti-CD3 monoclonal antibody hOKT3 γ 1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. *Diabetes* 2005;54:1763–9.
40. Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. *J Clin Gastroenterol* 2005;39:557–69.
41. Utsset TO. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. *J Rheumatol* 2002;29:1907–13.
42. Ghosh S, Goldin E, Gordon FH, Malchow HA, et al. for the Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. *N Engl J Med* 2003;348:24–32.
43. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, et al. for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med* 2006;354:899–910.
44. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, et al. for the SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med* 2006;354:911–23.
45. Sandborn WJ, Colombel JF, Enns R, Feagan BG, et al. for the International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) and the Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Groups. Natalizumab induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2005;353:1912–25.
46. Kleinschmidt-De Masters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. *N Engl J Med* 2005;353:369–74.
47. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. *N Engl J Med* 2005;353:375–81.
48. Van Assche G, Van Ranst M, Scot R, Dubois B, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. *N Engl J Med* 2005;353:362–8.
49. Yousry TA, Major EO, Ryschewitsch C, Fahle G, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *N Engl J Med* 2006;354:924–33.
50. Kremer JM, Westhovens R, Leon M, Di Giorgio E, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N Engl J Med* 2003;349:1907–15.
51. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: 12-month results of a phase IIIB, double-blind, randomized, placebo-controlled trial. *Arthritis Rheum* 2005;52:2263–71.
52. Genovese M, Becker JC, Schiff M, Luggen M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. *N Engl J Med* 2005;353:1114–23.
53. Emery P, Kosinski M, Li T, Martin M, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. *J Rheumatol* 2006;33:681–9.
54. Kliwinski C, Kukral D, Postelnek J, Krishnan B, et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. *J Autoimmun* 2005;25:165–71.
55. Gottlieb AB. Alefacept for psoriasis and psoriatic arthritis. *Ann Rheum Dis* 2005;64(Suppl):iv58–60.
56. Kraan MC, van Kuijk A, Dinant H, Goedkoop AY, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. *Arthritis Rheum* 2002;46:2776–84.
57. Papp K, Mease PJ, Garovoy M, et al. Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo-controlled study. *Int. Psoriasis Symposium, Toronto, June 2004.*
58. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. *Rheumatology* 2001;40:205–11.
59. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* 2004;350:2572–81.
60. Higashida J, Wun T, Schmidt S, Naguwa SM, et al. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor- α treatment. *J Rheumatol* 2005;32:2109–15.
61. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20: what do B-cells do? *Clin Immunol* 2005;117:207–13.
62. Eisenberg R. Update on rituximab. *Ann Rheum Dis* 2005;64(Suppl): iv55–7.
63. Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. *Ann Rheum Dis* 2002;61(Suppl II):ii96–9.
64. Tanaka S, Nakamura K, Takahashi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. *Immunol Rev* 2005;208:30–49.
65. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. *J Bone Miner Res* 2001;16:348–60.
66. Body JJ, Greipp P, Coleman RE, Facon T, et al. A phase I study of AMG-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. *Cancer* 2003;97(Suppl):887–92.
67. Becker PJ, Holloway D, Rasmussen AS, Murphy R, et al. A single-dose placebo controlled study of AMG-162, a fully human monoclonal antibody to RANKL, in postmenopausal women. *J Bone Miner Res* 2004;19: 1059–66.